Supply interruption for TANOVEA®-CA1

Dear Veterinary Professional,

This communication is to inform you that we are anticipating a temporary supply interruption for TANOVEA®-CA1 (rabacfosadine for injection) for the treatment of lymphoma in dogs.

Recent production-related challenges at our contract manufacturer, coupled with increased demand for TANOVEA-CA1, have resulted in a supply reduction that is anticipated to potentially span several months. It is important to note that there is no impact on product quality, so any TANOVEA-CA1 vials currently in stock are not affected.

As always, the pets in your care are our number one priority. To ensure that dogs currently being administered TANOVEA-CA1 can continue treatment and complete the five-dose protocol, we have decided to halt new patient starts on TANOVEA-CA1 while we work to normalize supply. Until we can fully support a patient’s entire treatment, our commercial partner, Elanco US Inc, will only be taking orders for current TANOVEA-CA1 patients for the remainder of supply on hand.

We understand this supply issue impacts veterinarians, pet owners and the dogs that are relying on TANOVEA-CA1, and I want to assure you that our team is working around the clock with our manufacturer to facilitate future production. While we cannot commit to a firm date for resolution, we will make every effort to provide ongoing updates at tanovea.com.

On behalf of all of us at VetDC and Elanco, I want to express gratitude for your support of TANOVEA-CA1. While VetDC is committed to resolving this issue, we are fortunate to have a partner in Elanco, with their dedicated specialty field force and consulting veterinarians, to help support customers through this process.

If you have any questions, please do not hesitate to reach out to the VetDC customer care team at 1-877-468-3832 or at support@vet-dc.com. Alternatively, feel free to reach out to your Elanco sales representative or contact Elanco customer service at 1-800-782-8977.

Sincerely,

Steven J. Roy
President & CEO
VetDC, Inc.